Meeting of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, 59388-59389 [2018-25439]
Download as PDF
<![CDATA[
59388
Federal Register / Vol. 83, No. 226 / Friday, November 23, 2018 / Notices
amozie on DSK3GDR082PROD with NOTICES1
federal government focus in the next
NAP for CARB—that are not already
included in the current plan—and why
are they the most important? Your
response can cover a range of priority
areas for human, animal, and
environmental health, including
surveillance, research and development,
stewardship practices, infection
prevention and control practices, and/or
other areas for consideration.
In preparing your response, please be
sure to:
Æ Consider how your response fits
into the existing One Health paradigm,
and how your proposed priority should
be further pursued by the U.S.
Government;
Æ Provide an answer that is feasible
and actionable by the U.S. Government;
Æ Limit your responses to no more
than two priorities for each of the five
goals (a maximum of 10 can be
submitted);
Æ Summarize your response for each
priority area in 250 words or less,
including its scientific justification;
Æ Indicate whether your response is
relevant domestically, internationally,
or both;
Æ Indicate the domain(s) to which
your response applies—human, animal,
and/or environmental health;
Æ Include citations to support your
response (references must be in the form
of an active link or citation; we will not
accept attachments. Peer-reviewed
citations and journal links are highly
encouraged.
Response to this RFI is voluntary.
Responders are free to address any or all
of the goals listed in the NAP. Please
note that the USG will not pay for
response preparation or for the use of
any information contained in the
response. The answers provided in this
RFI must not include any confidential
or proprietary data. Responses to this
notice are not offers and cannot be
accepted by the USG to form a binding
contract or issue a grant. Please be
aware that your comments will not be
posted publicly, however, they may be
made available to the public, in part or
in full, subject to applicable laws and
regulations.
More information can be found at
www.hhs.gov/ash/carb.
Dated: November 13, 2018.
Jomana F. Musmar,
Acting Designated Federal Officer,
Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria Committee
Manager.
[FR Doc. 2018–25435 Filed 11–21–18; 8:45 am]
BILLING CODE 4150–44–P
VerDate Sep<11>2014
18:33 Nov 21, 2018
Jkt 247001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on Combating AntibioticResistant Bacteria
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting is scheduled to be held
for the Presidential Advisory Council on
Combating Antibiotic-Resistant Bacteria
(Advisory Council). The meeting will be
open to the public; a public comment
session will be held during the meeting.
Pre-registration is required for members
of the public who wish to attend the
meeting and who wish to participate in
the public comment session. Individuals
who wish to attend the meeting and/or
send in their public comment via email
should send an email to CARB@hhs.gov.
Registration information is available on
the website https://www.hhs.gov/ash/
carb/ and must be completed by January
23, 2019; all in-person attendees must
pre-register by this date. Additional
information about registering for the
meeting and providing public comment
can be obtained at https://www.hhs.gov/
ash/carb/ on the Meetings page.
DATES: The meeting is scheduled to be
held on January 30, 2019, from 9:00 a.m.
to 5:00 p.m. and January 31, 2019, from
9:00 a.m. to 5:00 p.m. ET (times are
tentative and subject to change). The
confirmed times and agenda items for
the meeting will be posted on the
website for the Advisory Council at
https://www.hhs.gov/ash/carb/ when this
information becomes available. Preregistration for attending the meeting in
person is required to be completed no
later than January 23, 2019; public
attendance at the meeting is limited to
the available space.
ADDRESSES: U.S. Department of Health
and Human Services, Hubert H.
Humphrey Building, Great Hall, 200
Independence Avenue SW, Washington,
DC 20201.
The meeting can also be accessed
through a live webcast on the day of the
meeting. For more information, visit
https://www.hhs.gov/ash/carb/.
FOR FURTHER INFORMATION CONTACT: Dr.
Jomana Musmar, Acting Designated
Federal Officer, Presidential Advisory
Council on Combating AntibioticResistant Bacteria, Office of the
Assistant Secretary for Health, U.S.
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Department of Health and Human
Services, Room 715H, Hubert H.
Humphrey Building, 200 Independence
Avenue SW, Washington, DC 20201.
Phone: (202) 690–5566; email: CARB@
hhs.gov.
Under
Executive Order 13676, dated
September 18, 2014, authority was given
to the Secretary of HHS to establish the
Advisory Council, in consultation with
the Secretaries of Defense and
Agriculture. Activities of the Advisory
Council are governed by the provisions
of Public Law 92–463, as amended (5
U.S.C. App.), which sets forth standards
for the formation and use of federal
advisory committees.
The Advisory Council will provide
advice, information, and
recommendations to the Secretary of
HHS regarding programs and policies
intended to support and evaluate the
implementation of Executive Order
13676, including the National Strategy
for Combating Antibiotic-Resistant
Bacteria and the National Action Plan
for Combating Antibiotic-Resistant
Bacteria. The Advisory Council shall
function solely for advisory purposes.
In carrying out its mission, the
Advisory Council will provide advice,
information, and recommendations to
the Secretary regarding programs and
policies intended to preserve the
effectiveness of antibiotics by
optimizing their use; advance research
to develop improved methods for
combating antibiotic resistance and
conducting antibiotic stewardship;
strengthen surveillance of antibioticresistant bacterial infections; prevent
the transmission of antibiotic-resistant
bacterial infections; advance the
development of rapid point-of-care and
agricultural diagnostics; further research
on new treatments for bacterial
infections; develop alternatives to
antibiotics for agricultural purposes;
maximize the dissemination of up-todate information on the appropriate and
proper use of antibiotics to the general
public and human and animal
healthcare providers; and improve
international coordination of efforts to
combat antibiotic resistance.
The public meeting will be dedicated
to hosting stakeholders to explore
priority areas that have emerged since
the original National Action Plan on
Combating Antibiotic Resistant Bacteria
was launched in 2015. The meeting
agenda will be posted on the Advisory
Council website at https://www.hhs.gov/
ash/carb/ when it has been finalized.
All agenda items are tentative and
subject to change.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\23NON1.SGM
23NON1
Federal Register / Vol. 83, No. 226 / Friday, November 23, 2018 / Notices
Public attendance at the meeting is
limited to the available space.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Advisory Council at the
address/telephone number listed above
at least one week prior to the meeting.
For those unable to attend in person, a
live webcast will be available. More
information on registration and
accessing the webcast can be found at
https://www.hhs.gov/ash/carb/.
Members of the public will have the
opportunity to provide comments prior
to the Advisory Council meeting by
emailing CARB@hhs.gov. Public
comments should be sent in by
midnight January 23, 2019, and should
be limited to no more than one page. All
public comments received prior to
January 23, 2019, will be provided to
Advisory Council members; comments
are limited to five minutes per speaker.
Dated: November 16, 2018.
Tammy R. Beckham,
Acting Director, National Vaccine Program
Office.
[FR Doc. 2018–25439 Filed 11–21–18; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
amozie on DSK3GDR082PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Research Education Program for Clinical
Researchers and Clinicians (R25).
Date: November 27, 2018.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
VerDate Sep<11>2014
18:33 Nov 21, 2018
Jkt 247001
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; MultiSite Studies for System-Level
Implementation of Substance Use Prevention
and Treatment Services (R01; R34).
Date: November 27, 2018.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Workshops on the Use of Adolescent Brain
Cognitive Development (ABCD) Data (R25
Clinical Trial Not Allowed).
Date: November 29, 2018.
Time: 10:00 a.m. to 11:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research (R21 Clinical Trial Optional).
Date: December 5, 2018.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
59389
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Advancing Exceptional Research on HIV/
AIDS and Substance Abuse (R01, Clinical
Trial Optional).
Date: December 13, 2018.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: November 16, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25427 Filed 11–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Pharmacokinetic Analysis Resource Center
(8947).
Date: January 8, 2019.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
E:\FR\FM\23NON1.SGM
23NON1
]]>Agencies
[Federal Register Volume 83, Number 226 (Friday, November 23, 2018)]
[Notices]
[Pages 59388-59389]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25439]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (HHS) is hereby giving notice
that a meeting is scheduled to be held for the Presidential Advisory
Council on Combating Antibiotic-Resistant Bacteria (Advisory Council).
The meeting will be open to the public; a public comment session will
be held during the meeting. Pre-registration is required for members of
the public who wish to attend the meeting and who wish to participate
in the public comment session. Individuals who wish to attend the
meeting and/or send in their public comment via email should send an
email to [email protected]. Registration information is available on the
website https://www.hhs.gov/ash/carb/ and must be completed by January
23, 2019; all in-person attendees must pre-register by this date.
Additional information about registering for the meeting and providing
public comment can be obtained at https://www.hhs.gov/ash/carb/ on the
Meetings page.
DATES: The meeting is scheduled to be held on January 30, 2019, from
9:00 a.m. to 5:00 p.m. and January 31, 2019, from 9:00 a.m. to 5:00
p.m. ET (times are tentative and subject to change). The confirmed
times and agenda items for the meeting will be posted on the website
for the Advisory Council at https://www.hhs.gov/ash/carb/ when this
information becomes available. Pre-registration for attending the
meeting in person is required to be completed no later than January 23,
2019; public attendance at the meeting is limited to the available
space.
ADDRESSES: U.S. Department of Health and Human Services, Hubert H.
Humphrey Building, Great Hall, 200 Independence Avenue SW, Washington,
DC 20201.
The meeting can also be accessed through a live webcast on the day
of the meeting. For more information, visit https://www.hhs.gov/ash/carb/.
FOR FURTHER INFORMATION CONTACT: Dr. Jomana Musmar, Acting Designated
Federal Officer, Presidential Advisory Council on Combating Antibiotic-
Resistant Bacteria, Office of the Assistant Secretary for Health, U.S.
Department of Health and Human Services, Room 715H, Hubert H. Humphrey
Building, 200 Independence Avenue SW, Washington, DC 20201. Phone:
(202) 690-5566; email: [email protected].
SUPPLEMENTARY INFORMATION: Under Executive Order 13676, dated September
18, 2014, authority was given to the Secretary of HHS to establish the
Advisory Council, in consultation with the Secretaries of Defense and
Agriculture. Activities of the Advisory Council are governed by the
provisions of Public Law 92-463, as amended (5 U.S.C. App.), which sets
forth standards for the formation and use of federal advisory
committees.
The Advisory Council will provide advice, information, and
recommendations to the Secretary of HHS regarding programs and policies
intended to support and evaluate the implementation of Executive Order
13676, including the National Strategy for Combating Antibiotic-
Resistant Bacteria and the National Action Plan for Combating
Antibiotic-Resistant Bacteria. The Advisory Council shall function
solely for advisory purposes.
In carrying out its mission, the Advisory Council will provide
advice, information, and recommendations to the Secretary regarding
programs and policies intended to preserve the effectiveness of
antibiotics by optimizing their use; advance research to develop
improved methods for combating antibiotic resistance and conducting
antibiotic stewardship; strengthen surveillance of antibiotic-resistant
bacterial infections; prevent the transmission of antibiotic-resistant
bacterial infections; advance the development of rapid point-of-care
and agricultural diagnostics; further research on new treatments for
bacterial infections; develop alternatives to antibiotics for
agricultural purposes; maximize the dissemination of up-to-date
information on the appropriate and proper use of antibiotics to the
general public and human and animal healthcare providers; and improve
international coordination of efforts to combat antibiotic resistance.
The public meeting will be dedicated to hosting stakeholders to
explore priority areas that have emerged since the original National
Action Plan on Combating Antibiotic Resistant Bacteria was launched in
2015. The meeting agenda will be posted on the Advisory Council website
at https://www.hhs.gov/ash/carb/ when it has been finalized. All agenda
items are tentative and subject to change.
[[Page 59389]]
Public attendance at the meeting is limited to the available space.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify the Advisory Council at the address/telephone number listed
above at least one week prior to the meeting. For those unable to
attend in person, a live webcast will be available. More information on
registration and accessing the webcast can be found at https://www.hhs.gov/ash/carb/.
Members of the public will have the opportunity to provide comments
prior to the Advisory Council meeting by emailing [email protected]. Public
comments should be sent in by midnight January 23, 2019, and should be
limited to no more than one page. All public comments received prior to
January 23, 2019, will be provided to Advisory Council members;
comments are limited to five minutes per speaker.
Dated: November 16, 2018.
Tammy R. Beckham,
Acting Director, National Vaccine Program Office.
[FR Doc. 2018-25439 Filed 11-21-18; 8:45 am]
BILLING CODE 4150-44-P
